Analyst firms · Wells Fargo · VRDN

Wells Fargo VRDN price target and rating history

Viridian Therapeutics Inc. (VRDN) · Health Care

Wells Fargo rates Viridian Therapeutics Inc. (VRDN) Overweight with a $31 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on VRDN since April 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a VRDN price target in the last 12 months, the median target is $47. Wells Fargo's $31 is 34% below that.

Current rating
Overweight
Price target
$31
Median target, all firms
$47
Actions on VRDN
3

Wells Fargo price target on VRDN

$46$37$27202420252026
Wells Fargo price target on VRDN, each point a stated target, April 2023 to June 2026.

Every Wells Fargo rating on VRDN

How other firms rate VRDN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BofA SecuritiesBuy$47Nov 19, 2026
Wells FargoOverweight$31Jun 29, 2026
WedbushOutperform$47Dec 10, 2025
William BlairOutperformDec 3, 2025
Truist SecuritiesBuyNov 24, 2025

Questions about Wells Fargo and VRDN

What is Wells Fargo's price target for VRDN?
Wells Fargo's latest stated price target for Viridian Therapeutics Inc. (VRDN) is $31, from its action on Jun 29, 2026.
What is Wells Fargo's rating on VRDN?
Wells Fargo rates VRDN Overweight, a bullish rating, as of Jun 29, 2026.
When did Wells Fargo last change its view on VRDN?
On Jun 29, 2026, Wells Fargo upgrades to Overweight from Equal Weight, price target $31.
How does Wells Fargo's VRDN target compare with other analysts?
Across 3 firms with a VRDN price target in the last 12 months, the median target is $47. Wells Fargo's $31 is 34% below that.

All Wells Fargo ratingsVRDN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.